Big news from Pfizer and Partner on COVID-19 Experimental Vaccine

A vaccine is in sight.

Photo by Marc-Olivier Jodoin on Unsplash

Earlier in October, we published an article that contained information about Pfizer and partner BioNTech SE and their deal with the New Zealand Government that will supply them with Vaccines. The article further discussed how Pfizer and Co are waiting for regulatory approval and clinical trial results. You can view that article here:

In a recent update published on the Wall Street Journal, the test results of the COVID-19 vaccine was better than Pfizer could have hoped for. The vaccine proved more than 90% effective in the first 94 subjects who were infected, showed at least one symptom and then tested on.

Now it is important to note that the results are not complete yet. However, this is a big step for Pfizer and BioNTech, and a step closer to the world having its vaccine for this pandemic.

The U.S. Regulators have indicated that they will take time to review the results first. However, Pfizer indicated that they will be able to manufacture and distribute from as early as next month.

Source: The Wall Street Journal
Source: The Wall Street Journal

Investors were very excited and happy with the news from the partnership. Shares for both companies increased substantially as at 09:47 am.

The race for a Covid-19 vaccine has felt more like a Marathon. With economies and livelihoods devastated within its wake. Finally some good news, and some light at the end of the tunnel.

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Cloud Analytix

Cloud Analytix

Cloud Solution Provider. Passionate about cloud business efficiencies and security.